Nutlin‐3a treatment moderately increased blood glucose levels under STC feeding (Table S4, Supporting Information), which may be due to its negative effect on glucose‐stimulated insulin secretion, as we previously reported.[15] Strikingly, hepatic steatosis (Figure 7D–F) and inflammation (Figure S14D, Supporting Information) induced by CDAHFD were significantly alleviated by Nutlin‐3a treatment. The gene discussed is INS; the disease is Hepatic steatosis.